Current Report Filing (8-k)
October 22 2021 - 4:06PM
Edgar (US Regulatory)
false 0001750019 0001750019 2021-10-22 2021-10-22
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Act of 1934
Date of Report (Date of earliest event reported): October 22, 2021
TCR2 THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38811
|
|
47-4152751
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
100 Binney Street
Suite 710
Cambridge, Massachusetts 02142
(Address of principal executive offices, including zip code)
(617) 949-5200
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, $0.0001 Par Value
|
|
TCRR
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07
|
Submission of Matters to a Vote of Security Holders
|
On October 22, 2021, TCR2 Therapeutics Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders considered and voted on the two proposals set forth below, each of which is described in greater detail in the Company’s Proxy Statement filed with the Securities and Exchange Commission on September 3, 2021. The final voting results are set forth below.
Proposal 1 – Election of Class III Director Nominees
The stockholders of the Company elected Garry E. Menzel, Ph.D., Ansbert Gadicke, M.D., and Neil Gibson, Ph.D., as a Class III directors, for a three-year term ending at the annual meeting of stockholders to be held in 2024 and until each director’s successor has been duly elected and qualified or until his earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class III directors were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Votes
For
|
|
|
Votes
Withheld
|
|
|
Broker
Non-Votes
|
|
Garry E. Menzel, Ph.D.
|
|
|
23,062,461.41
|
|
|
|
3,651,095
|
|
|
|
3,803,285
|
|
Ansbert Gadicke, M.D.
|
|
|
23,230,375.41
|
|
|
|
3,483,181
|
|
|
|
3,803,285
|
|
Neil Gibson, Ph.D.
|
|
|
23,282,444.41
|
|
|
|
3,431,112
|
|
|
|
3,803,285
|
|
Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm
The stockholders of the Company ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. The results of the stockholders’ vote with respect to such ratification were as follows:
|
|
|
|
|
|
|
Votes
For
|
|
Votes
Against
|
|
Abstain
|
|
Broker
Non-Votes
|
30,489,743.41
|
|
21,712
|
|
5,386
|
|
0
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
TCR2 Therapeutics Inc.
|
|
|
|
|
|
|
|
|
|
|
/s/ Mayur (Ian) Somaiya
|
Date: October 22, 2021
|
|
|
|
By:
|
|
Mayur (Ian) Somaiya
|
|
|
|
|
|
|
Chief Financial Officer
|
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Sep 2024 to Oct 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Oct 2023 to Oct 2024